Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Ślebioda, Tomasz J ^a   Kmieć, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CLAUDIN; DEATH RECEPTOR 3; ETANERCEPT; FAS LIGAND; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN LIKE INDUCIBLE PROTEIN THAT COMPETES WITH GLYCOPROTEIN D FOR BINDING ON T CELL; MYOSIN LIGHT CHAIN KINASE; OCCLUDIN; PROTEIN; PROTEIN DCR3; PROTEIN P53; PROTEIN ZO1; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR LIKE MOLECULE 1A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UVOMORULIN; HERPESVIRUS ENTRY MEDIATOR LIGAND; TNFSF12 PROTEIN, HUMAN; TNFSF15 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

APOPTOSIS; CELL DIFFERENTIATION; CROHN DISEASE; CYTOKINE PRODUCTION; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; ULCERATIVE COLITIS; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; FAS LIGAND PROTEIN; HUMANS; INFLAMMATORY BOWEL DISEASES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 84904088078     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/325129     Document Type: Review

References (184)

1. Strober W., Fuss I., Mannon P., The fundamental basis of inflammatory bowel disease. Journal of Clinical Investigation 2007 117 3 514 521 2-s2.0-33847381116 10.1172/JCI30587 (Pubitemid 46348505)
2. Molodecky N. A., Kaplan G. G., Environmental risk factors for inflammatory bowel disease. Gastroenterology and Hepatology 2010 6 5 339 346 2-s2.0-77953307288
3. Hand T. W., Dos Santos L. M., Bouladoux N., Molloy M. J., Pagán A. J., Pepper M., Maynard C. L., Elson C. O. III, Belkaid Y., Acute gastrointestinal infection induces long-lived microbiota-specific T cell responses. Science 2012 337 6101 1553 1556 2-s2.0-84866436436 10.1126/science.1220961
4. Halme L., Paavola-Sakki P., Turunen U., Lappalainen M., Färkkilä M., Kontula K., Family and twin studies in inflammatory bowel disease. World Journal of Gastroenterology 2006 12 23 3668 3672 2-s2.0-33745473236 (Pubitemid 43950943)
5. Glocker E. O., Kotlarz D., Boztug K., Gertz E. M., Schäffer A. A., Noyan F., Perro M., Diestelhorst J., Allroth A., Murugan D., Hätscher N., Pfeifer D., Sykora K., Sauer M., Kreipe H., Lacher M., Nustede R., Woellner C., Baumann U., Salzer U., Koletzko S., Shah N., Segal A. W., Sauerbrey A., Buderus S., Snapper S. B., Grimbacher B., Klein C., Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. New England Journal of Medicine 2009 361 21 2033 2045 2-s2.0-70949087383 10.1056/NEJMoa0907206
6. Yamazaki K., McGovern D., Ragoussis J., Paolucci M., Butler H., Jewell D., Cardon L., Takazoe M., Tanaka T., Ichimori T., Saito S., Sekine A., Iida A., Takahashi A., Tsunoda T., Lathrop M., Nakamura Y., Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Human Molecular Genetics 2005 14 22 3499 3506 2-s2.0-27944464550 10.1093/hmg/ddi379 (Pubitemid 41672132)
7. Maeda S., Hsu L., Liu H., Bankston L. A., Iimura M., Kagnoff M. F., Eckmann L., Karin M., Nod2 mutation in Crohn's disease potentiates NF- B activity and IL-1 β processing. Science 2005 307 5710 734 738 2-s2.0-13244277880 10.1126/science.1103685 (Pubitemid 40194645)
8. Hampe J., Franke A., Rosenstiel P., Till A., Teuber M., Huse K., Albrecht M., Mayr G., De La Vega F. M., Briggs J., Günther S., Prescott N. J., Onnie C. M., Häsler R., Sipos B., Fölsch U. R., Lengauer T., Platzer M., Mathew C. G., Krawczak M., Schreiber S., A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nature Genetics 2007 39 2 207 211 2-s2.0-33846627302 10.1038/ng1954 (Pubitemid 46184351)
9. Parkes M., Barrett J. C., Prescott N. J., Tremelling M., Anderson C. A., Fisher S. A., Roberts R. G., Nimmo E. R., Cummings F. R., Soars D., Drummond H., Lees C. W., Khawaja S. A., Bagnall R., Burke D. A., Todhunter C. E., Ahmad T., Onnie C. M., McArdle W., Strachan D., Bethel G., Bryan C., Lewis C. M., Deloukas P., Forbes A., Sanderson J., Jewell D. P., Satsangi J., Mansfield J. C., Cardon L., Mathew C. G., Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genetics 2007 39 7 830 832 2-s2.0-34347338690 10.1038/ng2061 (Pubitemid 47014496)
10. Lin Z., Poritz L., Franke A., Li T. Y., Ruether A., Byrnes K. A., Wang Y., Gebhard A. W., MacNeill C., Thomas N. J., Schreiber S., Koltun W. A., Genetic association of DLG5 R30Q with familial and sporadic inflammatory bowel disease in men. Disease Markers 2009 27 5 193 201 2-s2.0-77249166049 10.3233/DMA-2009-0662
11. Brand S., Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009 58 8 1152 1167 2-s2.0-67650224449 10.1136/gut.2008.163667
12. Bamias G., Kaltsa G., Ladas S. D., Cytokines in the pathogenesis of ulcerative colitis. Discovery Medicine 2011 11 60 459 467 2-s2.0-84863683006
13. Šventoraityte J., Žvirbliene A., Kiudelis G., Žalinkevičius R., Žvirbliene A., Praškevičius A., Kupčinskas L., Tamošiunas V., Immune system alterations in patients with inflammatory bowel disease during remission. Medicina 2008 44 1 27 33 2-s2.0-40949151599
14. Pak S., Holland N., Garnett E. A., Mileti E., Mahadevan U., Beckert R., Kanwar B., Heyman M. B., Cytokine profiles in peripheral blood of children and adults with Crohn disease. Journal of Pediatric Gastroenterology and Nutrition 2012 54 6 769 775 2-s2.0-84861334014 10.1097/MPG.0b013e3182455bb3
15. Holland N., Dong J., Garnett E., Shaikh N., Huen K., Harmatz P., Olive A., Winter H. S., Gold B. D., Cohen S. A., Baldassano R. N., Kirschner B. S., Heyman M. B., Reduced intracellular T-helper 1 interferon-gamma in blood of newly diagnosed children with Crohn's disease and age-related changes in Th1/Th2 cytokine profiles. Pediatric Research 2008 63 3 257 262 2-s2.0-39749125599 10.1203/PDR.0b013e318163a897 (Pubitemid 351301453)
16. Fuss I. J., Strober W., The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunology 2008 1 supplement 1 S31 S33 2-s2.0-54349118972 10.1038/mi.2008.40
17. Oliphant C. J., Barlow J. L., Mckenzie A. N. J., Insights into the initiation of type 2 immune responses. Immunology 2011 134 4 378 385 2-s2.0-80355142109 10.1111/j.1365-2567.2011.03499.x
18. Heller F., Fromm A., Gitter A. H., Mankertz J., Schulzke J.-D., Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function. Mucosal Immunology 2008 1 supplement 1 S58 S61 2-s2.0-54349114505 10.1038/mi.2008.46
19. Mannon P. J., Hornung R. L., Yang Z., Yi C., Groden C., Friend J., Yao M., Strober W., Fuss I. J., Suppression of inflammation in ulcerative colitis by interferon- β -1a is accompanied by inhibition of IL-13 production. Gut 2011 60 4 449 455 2-s2.0-79952532799 10.1136/gut.2010.226860
20. Aggarwal B. B., Gupta S. C., Kim J. H., Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012 119 3 651 665 2-s2.0-84862962823 10.1182/blood-2011-04-325225
21. Aggarwal B. B., Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology 2003 3 9 745 756 2-s2.0-0141465062 10.1038/nril184 (Pubitemid 41070815)
22. Arch R. H., Gedrich R. W., Thompson C. B., Tumor necrosis factor receptor-associated factors (TRAFs)-a family of adapter proteins that regulates life and death. Genes and Development 1998 12 18 2821 2830 2-s2.0-0032530455 (Pubitemid 28440141)
23. Atreya R., Zimmer M., Bartsch B., Waldner M. J., Atreya I., Neumann H., Hildner K., Hoffman A., Kiesslich R., Rink A. D., Rau T. T., Rosejohn S., Kessler H., Schmidt J., Neurath M. F., Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14 + macrophages. Gastroenterology 2011 141 6 2026 2038 2-s2.0-81855209849 10.1053/j.gastro.2011.08.032
24. Wajant H., Pfizenmaier K., Scheurich P., Tumor necrosis factor signaling. Cell Death and Differentiation 2003 10 1 45 65 2-s2.0-0037276438 10.1038/sj.cdd.4401189 (Pubitemid 36511832)
25. Watts T. H., TNF/TNFR family members in costimulation of T cell responses. Annual Review of Immunology 2005 23 23 68 2-s2.0-17644389199 10.1146/annurev.immunol.23.021704.115839 (Pubitemid 40563164)
26. Croft M., The role of TNF superfamily members in T-cell function and diseases. Nature Reviews Immunology 2009 9 4 271 285 2-s2.0-63149163677 10.1038/nri2526
27. Nolte M. A., Van Olffen R. W., Van Gisbergen K. P. J. M., Van Lier R. A. W., Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunological Reviews 2009 229 1 216 231 2-s2.0-65349144269 10.1111/j.1600-065X. 2009.00774.x
28. Wang C., Lin G. H., McPherson A. J., Watts T. H., Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunological Reviews 2009 229 1 192 215 2-s2.0-65349153714 10.1111/j.1600-065X.2009.00765.x
29. Croft M., So T., Duan W., Soroosh P., The significance of OX40 and OX40L to T-cell biology and immune disease. Immunological Reviews 2009 229 1 173 191 2-s2.0-65349112520 10.1111/j.1600-065X.2009.00766.x
30. Pappu B. P., Borodovsky A., Zheng T. S., Yang X., Wu P., Dong X., Weng S., Browning B., Scott M. L., Li M., Su L., Tian Q., Schneider P., Flavell R. A., Dong C., Burkly L. C., TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. Journal of Experimental Medicine 2008 205 5 1049 1062 2-s2.0-43549087629 10.1084/jem.20071364 (Pubitemid 351679681)
31. Kmiec Z., Cytokines in inflammatory bowel disease. Archivum Immunologiae et Therapia Experimentalis 1998 46 143 155 (Pubitemid 28319262)
32. Bamias G., Corridoni D., Pizarro T. T., Cominelli F., New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine 2012 59 3 451 459 2-s2.0-84864993041 10.1016/j.cyto.2012.06.014
33. Meylan F., Richard A. C., Siegel R. M., TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunological Reviews 2011 244 1 188 196 2-s2.0-80054868741 10.1111/j.1600-065X.2011.01068.x
34. Ueyama H., Kiyohara T., Sawada N., Isozaki K., Kitamura S., Kondo S., Miyagawa J., Kanayama S., Shinomura Y., Ishikawa H., Ohtani T., Nezu R., Nagata S., Matsuzawa Y., High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut 1998 43 1 48 55 2-s2.0-7344245990 (Pubitemid 28335489)
35. Yukawa M., Iizuka M., Horie Y., Yoneyama K., Shirasaka T., Itou H., Komatsu M., Fukushima T., Watanabe S., Systemic and local evidence of increased Fas-mediated apoptosis in ulcerative colitis. International Journal of Colorectal Disease 2002 17 2 70 76 2-s2.0-0036939333 10.1007/s003840100340 (Pubitemid 36067751)
36. Souza H. S. P., Tortori C. J. A., Castelo-Branco M. T. L., Carvalho A. T. P., Margallo V. S., Delgado C. F., Dines I., Elia C. C. S., Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways. International Journal of Colorectal Disease 2005 20 3 277 286 2-s2.0-17644422766 10.1007/s00384-004-0639-8 (Pubitemid 40558036)
37. Cohavy O., Zhou J., Ware C. F., Targan S. R., LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling. Journal of Immunology 2005 174 2 646 653 2-s2.0-11844252673 (Pubitemid 40094256)
38. Begue B., Wajant H., Bambou J., Dubuquoy L., Siegmund D., Beaulieu J., Canioni D., Berrebi D., Brousse N., Desreumaux P., Schmitz J., Lentze M. J., Goulet O., Cerf-Bensussan N., Ruemmele F. M., Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006 130 7 1962 1974 2-s2.0-33744546642 10.1053/j.gastro.2006. 03.022 (Pubitemid 43816954)
39. Kawashima R., Kawamura Y. I., Oshio T., Son A., Yamazaki M., Hagiwara T., Okada T., Inagakiohara K., Wu P., Szak S., Kawamura Y. J., Konishi F., Miyake O., Yano H., Saito Y., Burkly L. C., Dohi T., Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in MiceA pathway associated with ulcerative colitis. Gastroenterology 2011 141 6 e2118 e2119 2-s2.0-81855228077 10.1053/j.gastro. 2011.08.040
40. Cabal-Hierro L., Lazo P. S., Signal transduction by tumor necrosis factor receptors. Cellular Signalling 2012 24 6 1297 1305 2-s2.0-84859072803 10.1016/j.cellsig.2012.02.006
41. Locksley R. M., Killeen N., Lenardo M. J., The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001 104 4 487 501 2-s2.0-0035936797 10.1016/S0092-8674(01)00237-9 (Pubitemid 32201945)
42. Faustman D. L., Davis M., TNF receptor 2 and disease: autoimmunity and regenerative medicine. Frontiers in Immunology 2013 4 478
43. Leppkes M., Roulis M., Neurath M. F., Kollias G., Becker C., The pleiotropic functions of TNF-alpha in the regulation of the intestinal epithelial response to inflammation. International Immunology 2014
44. Van Hauwermeiren F., Armaka M., Karagianni N., Kranidioti K., Vandenbroucke R. E., Loges S., Van Roy M., Staelens J., Puimège L., Palagani A., Vanden Berghe W., Victoratos P., Carmeliet P., Libert C., Kollias G., Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium. Journal of Clinical Investigation 2013 123 6 2590 2603 2-s2.0-84878589884 10.1172/JCI65624
45. Bamias G., Jia L. G., Cominelli F., The tumor necrosis factor-like cytokine 1A/death receptor 3 cytokine system in intestinal inflammation. Current Opinion in Gastroenterology 2013 29 6 597 602 10.1097/MOG.0b013e328365d3a2
46. Schreiber T. H., Podack E. R., Immunobiology of TNFSF15 and TNFRSF25. Immunologic Research 2013 57 1-3 3 11 10.1007/s12026-013-8465-0
47. Lettau M., Paulsen M., Kabelitz D., Janssen O., FasL expression and reverse signalling. Results and Problems in Cell Differentiation 2009 49 49 61 2-s2.0-77649328967 10.1007/400-2008-21
48. Chen L., Park S., Turner J. R., Peter M. E., Cell death in the colonic epithelium during inflammatory bowel diseases: CD95/Fas and beyond. Inflammatory Bowel Diseases 2010 16 6 1071 1076 2-s2.0-77952715680 10.1002/ibd.21191
49. Wang J., Anders R. A., Wang Y., Turner J. R., Abraham C., Pfeffer K., Fu Y., The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. Journal of Immunology 2005 174 12 8173 8182 2-s2.0-20444413440 (Pubitemid 40806329)
50. Reenaers C., Franchimont N., Oury C., Belaiche J., Malaise M., Bours V., Theatre E., Delvenne P., Louis E., Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease. Scandinavian Journal of Gastroenterology 2008 43 11 1334 1345 2-s2.0-54349103802 10.1080/00365520802200010
51. Dohi T., Borodovsky A., Wu P., Shearstone J. R., Kawashima R., Runkel L., Rajman L., Dong X., Scott M. L., Michaelson J. S., Jakubowski A., Burkly L. C., TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology 2009 136 3 912 923 2-s2.0-60449110144 10.1053/j.gastro.2008.11.017
52. Murch S. H., Lamkin V. A., Savage M. O., Walker-Smith J. A., MacDonald T. T., Serum concentrations of tumour necrosis factor α in childhood chronic inflammatory bowel disease. Gut 1991 32 8 913 917 2-s2.0-0025912981
53. Dionne S., Hiscott J., D'Agata I., Duhaime A., Seidman E. G., Quantitative PCR analysis of TNF- α and IL-1 β mRNA levels in pediatric IBD mucosal biopsies. Digestive Diseases and Sciences 1997 42 7 1557 1566 2-s2.0-0030842468 10.1023/A:1018895500721 (Pubitemid 27339380)
54. Matsuda R., Koide T., Tokoro C., Yamamoto T., Godai T., Morohashi T., Fujita Y., Takahashi D., Kawana I., Suzuki S., Umemura S., Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid Naïve ulcerative colitis during active and quiescent disease. Inflammatory Bowel Diseases 2009 15 3 328 334 2-s2.0-66149152303 10.1002/ibd.20759
55. Owczarek D., Cibor D., Głowacki M. K., Cieśla A., Mach P., TNF- α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn's disease and ulcerative colitis. Polskie Archiwum Medycyny Wewnetrznej 2012 122 12 616 623 2-s2.0-84872289433
56. Maeda M., Watanabe N., Neda H., Yamauchi N., Okamoto T., Sasaki H., Tsuji Y., Akiyama S., Tsuji N., Niitsu Y., Serum tumor necrosis factor activity in inflammatory bowel disease. Immunopharmacology and Immunotoxicology 1992 14 3 451 461 2-s2.0-0026780966
57. Murch S. H., Braegger C. P., Walker-Smith J. A., MacDonald T. T., Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993 34 12 1705 1709 2-s2.0-0027486125 (Pubitemid 23353163)
58. Stevens C., Walz G., Singaram C., Lipman M. L., Zanker B., Muggia A., Antonioli D., Peppercorn M. A., Strom T. B., Tumor necrosis factor- α interleukin-1 β and interleukin-6 expression in inflammatory bowel disease. Digestive Diseases and Sciences 1992 37 6 818 826 2-s2.0-0026689516 10.1007/BF01300378
59. Hyams J. S., Treem W. R., Eddy E., Wyzga N., Moore R. E., Tumor necrosis factor- α is not elevated in children with inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 1991 12 2 233 236 2-s2.0-0025728070
60. Perrier C., De Hertogh G., Cremer J., Vermeire S., Rutgeerts P., Van Assche G., Szymkowski D. E., Ceuppens J. L., Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflammatory Bowel Diseases 2013 19 2 246 253 2-s2.0-84876419725 10.1002/ibd.23023
61. Mizoguchi E., Mizoguchi A., Takedatsu H., Cario E., De Jong Y. P., Ooi C. J., Xavier R. J., Terhorst C., Podolsky D. K., Bhan A. K., Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology 2002 122 1 134 144 2-s2.0-0036142256 (Pubitemid 34049202)
62. Holtmann M. H., Douni E., Schutz M., Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo. European Journal of Immunology 2002 32 11 3142 3151 (Pubitemid 35414872)
63. Ma T. Y., Iwamoto G. K., Hoa N. T., Akotia V., Pedram A., Boivin M. A., Said H. M., TNF- α -induced increase in intestinal epithelial tight junction permeability requires NF- B activation. American Journal of Physiology-Gastrointestinal and Liver Physiology 2004 286 3 G367 G376 2-s2.0-1342280570 (Pubitemid 38250308)
64. Fréour T., Jarry A., Bach-Ngohou K., Dejoie T., Bou-Hanna C., Denis M. G., Mosnier J., Laboisse C. L., Masson D., TACE inhibition amplifies TNF- α -mediated colonic epithelial barrier disruption. International Journal of Molecular Medicine 2009 23 1 41 48 2-s2.0-61749084909 10.3892/ijmm/00000099
65. Wang F., Schwarz B. T., Graham W. V., Wang Y., Su L., Clayburgh D. R., Abraham C., Turner J. R., IFN- γ -induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology 2006 131 4 1153 1163 2-s2.0-33749466490 10.1053/j.gastro.2006.08.022 (Pubitemid 44515106)
66. Rose-John S., ADAM17, shedding, TACE as therapeutic targets. Pharmacological Research 2013 71 19 22 2-s2.0-84876110045 10.1016/j.phrs.2013. 01.012
67. Cesaro A., Abakar-Mahamat A., Brest P., Lassalle S., Selva E., Filippi J., Hébuterne X., Hugot J., Doglio A., Galland F., Naquet P., Vouret-Craviari V., Mograbi B., Hofman P. M., Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. American Journal of Physiology-Gastrointestinal and Liver Physiology 2009 296 6 G1332 G1343 2-s2.0-67049134408 10.1152/ajpgi.90641.2008
68. Franzè E., Caruso R., Stolfi C., Sarra M., Cupi M. L., Ascolani M., Sedda S., Antenucci C., Ruffa A., Caprioli F., MacDonald T. T., Pallone F., Monteleone G., High expression of the "A disintegrin and metalloprotease" 19 (ADAM19), a sheddase for TNF-a in the mucosa of patients with inflammatory bowel diseases. Inflammatory Bowel Diseases 2013 19 3 501 511 2-s2.0-84876368553 10.1097/MIB.0b013e31828028e8
69. Vandenbroucke R. E., Dejonckheere E., Van Hauwermeiren F., Lodens S., De Rycke R., Van Wonterghem E., Staes A., Gevaert K., López-Otin C., Libert C., Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Molecular Medicine 2013 5 7 932 948 2-s2.0-84880026950 10.1002/emmm.201202100
70. Su L., Nalle S. C., Shen L., Turner E. S., Singh G., Breskin L. A., Khramtsova E. A., Khramtsova G., Tsai P., Fu Y., Abraham C., Turner J. R., TNFR2 activates mlck-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology 2013 145 2 407 415 2-s2.0-84880611949 10.1053/j.gastro.2013.04.011
71. Marchiando A. M., Shen L., Graham W. V., Edelblum K. L., Duckworth C. A., Guan Y., Montrose M. H., Turner J. R., Watson A. J. M., The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology 2011 140 4 1208 1218 2-s2.0-79953174256 10.1053/j.gastro.2011.01.004
72. Goretsky T., Dirisina R., Sinh P., Mittal N., Managlia E., Williams D. B., Posca D., Ryu H., Katzman R. B., Barrett T. A., P53 mediates TNF-induced epithelial cell apoptosis in IBD. American Journal of Pathology 2012 181 4 1306 1315 2-s2.0-84866491630 10.1016/j.ajpath.2012.06.016
73. Cunningham K. E., Turner J. R., Myosin light chain kinase: pulling the strings of epithelial tight junction function. Annals of the New York Academy of Sciences 2012 1258 1 34 42 2-s2.0-84862853385 10.1111/j.1749-6632.2012.06526.x
74. Blair S. A., Kane S. V., Clayburgh D. R., Turner J. R., Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Laboratory Investigation 2006 86 2 191 201 2-s2.0-30944443377 10.1038/labinvest.3700373 (Pubitemid 43117598)
75. Yamaoka T., Yan F., Cao H., Hobbs S. S., Dise R. S., Tong W., Polk D. B., Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America 2008 105 33 11772 11777 2-s2.0-50149105621 10.1073/pnas.0801463105
76. Hobbs S. S., Goettel J. A., Liang D., Yan F., Edelblum K. L., Frey M. R., Mullane M. T., Polk D. B., TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. American Journal of Physiology-Gastrointestinal and Liver Physiology 2011 301 2 G220 G229 2-s2.0-79961004564 10.1152/ajpgi.00383.2010
77. Xu K., Wang L., Shu H. K., COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget 2014 5 5 1241 1252
78. Lukas M., Inflammatory bowel disease as a risk factor for colorectal cancer. Digestive Diseases 2010 28 4-5 619 624 2-s2.0-78649368287 10.1159/000320276
79. Pache I., Rogler G., Felley C., TNF- α blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss Medical Weekly 2009 139 19-20 278 287 2-s2.0-67650079131
80. Boyce E. G., Halilovic J., Stan-Ugbene O., Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor- α inhibitor. Clinical Therapeutics 2010 32 10 1681 1703 2-s2.0-78650589350 10.1016/j.clinthera.2010.09.003
81. Dretzke J., Edlin R., Round J., Connock M., Hulme C., Czeczot J., Fry-Smith A., McCabe C., Meads C., A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF- α) inhibitors, adalimumab and infliximab, for crohn's disease. Health Technology Assessment 2011 15 6 1 250 2-s2.0-79951639158 10.3310/hta15060
82. Nielsen O. H., Seidelin J. B., Munck L. K., Rogler G., Use of biological molecules in the treatment of inflammatory bowel disease. Journal of Internal Medicine 2011 270 1 15 28 2-s2.0-79551493970 10.1111/j.1365-2796.2011.02344.x
83. Lawson M. M., Thomas A. G., Akobeng A. K., Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006 3 CD005112 2-s2.0-33750105599
84. Wilhelm S. M., McKenney K. A., Rivait K. N., Kale-Pradhan P. B., A review of infliximab use in ulcerative colitis. Clinical Therapeutics 2008 30 2 223 230 2-s2.0-41549090435 10.1016/j.clinthera.2008.02.014 (Pubitemid 351474384)
85. Reinisch W., Sandborn W. J., Hommes D. W., D'Haens G., Hanauer S., Schreiber S., Panaccione R., Fedorak R. N., Tighe M. B., Huang B., Kampman W., Lazar A., Thakkar R., Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011 60 6 780 787 2-s2.0-79955859430 10.1136/gut.2010. 221127
86. Sandborn W. J., Van Assche G., Reinisch W., Colombel J., D'Haens G., Wolf D. C., Kron M., Tighe M. B., Lazar A., Thakkar R. B., Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012 142 2 257 265 2-s2.0-84856163835 10.1053/j.gastro.2011.10.032
87. Sandborn W. J., Feagan B. G., Marano C., Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014 146 1 85 95
88. Sandborn W. J., Feagan B. G., Marano C., Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014 146 1 96.e1 109.e1 10.1053/j.gastro.2013.06.010
89. Peyrin-Biroulet L., Deltenre P., de Suray N., Branche J., Sandborn W. J., Colombel J., Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clinical Gastroenterology and Hepatology 2008 6 6 644 653 2-s2.0-44649187924 10.1016/j.cgh.2008.03.014 (Pubitemid 351783447)
90. Nielsen O. H., Ainsworth M. A., Tumor necrosis factor inhibitors for inflammatory bowel disease. New England Journal of Medicine 2013 369 8 754 762 2-s2.0-84882762733 10.1056/NEJMct1209614
91. Yarur A. J., Abreu M. T., Deshpande A. R., Therapeutic drug monitoring in patients with inflammatory bowel disease. World Journal of Gastroenterology 2014 20 13 3475 3484 10.3748/wjg.v20.i13.3475
92. Danese S., Fiorino G., Peyrin-Biroulet L., Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Annals of Internal Medicine 2014 160 10 704 711 10.7326/M13-2403
93. Ben-Horin S., Kopylov U., Chowers Y., Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmunity Reviews 2014 126 6 1593 1610 2-s2.0-84879349904 10.1016/j.autrev.2013.06.002
94. Altwegg R., Vincent T., TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators of Inflammation 2014 2014 7 172821 10.1155/2014/172821
95. Lichtenstein G. R., Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therapeutic Advances in Gastroenterology 2013 6 4 269 293 2-s2.0-84878299137 10.1177/1756283X13479826
96. Campi P., Benucci M., Manfredi M., Demoly P., Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor- α antagonists. Current Opinion in Allergy and Clinical Immunology 2007 7 5 393 403 2-s2.0-34548690769 10.1097/ACI.0b013e3282ef96df (Pubitemid 47415282)
97. Barbaud A., Granel F., Waton J., Poreaux C., How to manage hypersensitivity reactions to biological agents? European Journal of Dermatology 2011 21 5 667 674 2-s2.0-80054906829 10.1684/ejd.2011.1468
98. Deepak P., Stobaugh D. J., Ehrenpreis E. D., Infectious complications of TNF-alpha inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. Journal of Gastrointestinal and Liver Diseases 2013 22 3 269 276
99. Lozeron P., Denier C., Lacroix C., Adams D., Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-a-blocker therapy. Archives of Neurology 2009 66 4 490 497 2-s2.0-65249085647 10.1001/archneurol.2009.11
100. Deepak P., Stobaugh D. J., Sherid M., Sifuentes H., Ehrenpreis E. D., Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Alimentary Pharmacology and Therapeutics 2013 38 4 388 396 2-s2.0-84880265802 10.1111/apt.12385
101. Moris G., Inflammatory bowel disease: an increased risk factor for neurologic complications. World Journal of Gastroenterology 2014 20 5 1228 1237
102. Fiorino G., Danese S., Pariente B., Allez M., Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF- α agents. Autoimmunity Reviews 2014 13 1 15 19 2-s2.0-84879456500 10.1016/j.autrev.2013.06.005
103. Tillack C., Ehmann L. M., Friedrich M., Laubender R. P., Papay P., Vogelsang H., Stallhofer J., Beigel F., Bedynek A., Wetzke M., Maier H., Koburger M., Wagner J., Glas J., Diegelmann J., Koglin S., Dombrowski Y., Schauber J., Wollenberg A., Brand S., Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014 63 4 567 577 2-s2.0-84874738773 10.1136/gutjnl-2012-302853
104. Van den Brande J. M. H., Braat H., Van den Brink G. R., Versteeg H. H., Bauer C. A., Hoedemaeker I., Van Montfrans C., Hommes D. W., Peppelenbosch M. P., Van Deventer S. J. H., Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003 124 7 1774 1785 2-s2.0-0038047689 10.1016/S0016-5085(03) 00382-2 (Pubitemid 36666774)
105. Mudter J., Neurath M. F., Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 2007 56 2 293 303 2-s2.0-33847000579 10.1136/gut.2005.090464
106. Veltkamp C., Anstaett M., Wahl K., Möller S., Gangl S., Bachmann O., Hardtke-Wolenski M., Länger F., Stremmel W., Manns M. P., Schulze-Osthoff K., Bantel H., Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNF α treatment. Gut 2011 60 10 1345 1353 2-s2.0-80052573212 10.1136/gut.2010.217117
107. Boschetti G., Nancey S., Sardi F., Roblin X., Flourié B., Kaiserlian D., Therapy with anti-TNF α antibody enhances number and function of Foxp3+ regulatory T cells in inflammatory bowel diseases. Inflammatory Bowel Diseases 2011 17 1 160 170 2-s2.0-78650080500 10.1002/ibd.21308
108. Vos A. C., Wildenberg M. E., Duijvestein M., Verhaar A. P., Van Den Brink G. R., Hommes D. W., AntiTumor necrosis factor- α antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 2011 140 1 221 230 2-s2.0-78650459480 10.1053/j.gastro.2010.10.008
109. Vos A. C., Wildenberg M. E., Arijs I., Duijvestein M., Verhaar A. P., De Hertogh G., Vermeire S., Rutgeerts P., Van Den Brink G. R., Hommes D. W., Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. Inflammatory Bowel Diseases 2012 18 3 401 408 2-s2.0-84857373545 10.1002/ibd.21818
110. Leal R. F., Planell N., Kajekar R., Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFalpha therapy. Gut 2014 10.1136/gutjnl-2013-306518
111. Suenaert P., Bulteel V., Lemmens L., Noman M., Geypens B., Assche G. V., Geboes K., Ceuppens J. L., Rutgeerts P., Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. American Journal of Gastroenterology 2002 97 8 2000 2004 2-s2.0-0036678630 10.1016/S0002-9270(02) 04271-5
112. Fries W., Muja C., Crisafulli C., Costantino G., Longo G., Cuzzocrea S., Mazzon E., Infliximab and etanercept are equally effective in reducing enterocyte apoptosis in experimental colitis. International Journal of Medical Sciences 2008 5 4 169 180 2-s2.0-47349097005 (Pubitemid 352000027)
113. Fischer A., Gluth M., Pape U., Wiedenmann B., Theuring F., Baumgart D. C., Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF- α on tight junction proteins and signaling pathways in intestinal epithelial cells. American Journal of Physiology-Gastrointestinal and Liver Physiology 2013 304 11 G970 G979 2-s2.0-84878667737 10.1152/ajpgi.00183.2012
114. Eder P., Lykowska-Szuber L., Krela-Kazmierczak I., Anti-TNF antibodies do not induce the apoptosis of lamina propria mononuclear cells in uninflamed intestinal tissue in patients with Crohn's disease. Folia Histochemica et Cytobiologica 2013 51 239 243 10.5603/FHC.2013.0034
115. Eder P., Lykowska-Szuber L., Krela-Kazmierczak I., Stawczyk-Eder K., Zabel M., Linke K., The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease-an immunohistochemical study. Journal of Crohn's and Colitis 2013 7 9 706 716 2-s2.0-84881554609 10.1016/j.crohns.2012.09.006
116. Scallon B., Cai A., Solowski N., Rosenberg A., Song X., Shealy D., Wagner C., Binding and functional comparisons of two types of tumor necrosis factor antagonists. Journal of Pharmacology and Experimental Therapeutics 2002 301 2 418 426 2-s2.0-0036229932 10.1124/jpet.301.2.418 (Pubitemid 34429950)
117. Sandborn W. J., Hanauer S. B., Katz S., Safdi M., Wolf D. G., Baerg R. D., Tremaine W. J., Johnson T., Diehl N. N., Zinsmeister A. R., Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001 121 5 1088 1094 2-s2.0-0034754477 (Pubitemid 33022088)
118. Migone T. S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., Hong J. S., Perry J. W., Chen S., Zhou J. X. H., Cho Y. H., Ullrich S., Kanakaraj P., Carrell J., Boyd E., Olsen H. S., Hu G., Pukac L., Liu D., Ni J., Kim S., Gentz R., Feng P., Moore P. A., Ruben S. M., Wei P., TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002 16 3 479 492 2-s2.0-18344385475 10.1016/S1074-7613(02)00283-2 (Pubitemid 34260924)
119. Metheny-Barlow L. J., Li L. Y., Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis. Seminars in Ophthalmology 2006 21 1 49 58 2-s2.0-33646937417 10.1080/08820530500511446 (Pubitemid 43879516)
120. Chew L. J., Pan H., Yu J., Tian S., Huang W., Zhang J. Y., Pang S., Li L., A novel secreted splice variant of vascular endothelial cell growth inhibitor. The FASEB Journal 2002 16 7 742 744 2-s2.0-0036580698
121. Zhang N., Sanders A. J., Ye L., Vascular endothelial growth inhibitor in human cancer (Review). International Journal of Molecular Medicine 2009 24 1 3 8
122. Fang L., Adkins B., Deyev V., Podack E. R., Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. Journal of Experimental Medicine 2008 205 5 1037 1048 2-s2.0-43549110073 10.1084/jem.20072528 (Pubitemid 351679680)
123. Meylan F., Davidson T. S., Kahle E., Kinder M., Acharya K., Jankovic D., Bundoc V., Hodges M., Shevach E. M., Keane-Myers A., Wang E. C. Y., Siegel R. M., The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 2008 29 1 79 89 2-s2.0-46749097474 10.1016/j.immuni.2008.04.021
124. Zhang J., Wang X., Fahmi H., Wojcik S., Fikes J., Yu Y., Wu J., Luo H., Role of TL1A in the pathogenesis of rheumatoid arthritis. Journal of Immunology 2009 183 8 5350 5357 2-s2.0-76649096907 10.4049/jimmunol.0802645
125. Bamias G., Martin C. III, Marini M., Hoang S., Mishina M., Ross W. G., Sachedina M. A., Friel C. M., Mize J., Bickston S. J., Pizarro T. T., Wei P., Cominelli F., Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. Journal of Immunology 2003 171 9 4868 4874 2-s2.0-10744225786 (Pubitemid 37310609)
126. Prehn J. L., Mehdizadeh S., Landers C. J., Luo X., Cha S. C., Wei P., Targan S. R., Potential role for TL1A, the new TNF-family member and potent costimulator of IFN- γ in mucosal inflammation. Clinical Immunology 2004 112 1 66 77 2-s2.0-2942652655 10.1016/j.clim.2004.02.007 (Pubitemid 38781059)
127. Kim S., Zhang L., Identification of naturally secreted soluble form of TL1A, a TNF-like cytokine. Journal of Immunological Methods 2005 298 1-2 1 8 2-s2.0-17444421131 10.1016/j.jim.2004.12.019 (Pubitemid 40545088)
128. Prehn J. L., Thomas L. S., Landers C. J., Yu Q. T., Michelsen K. S., Targan S. R., The T cell costimulator TL1A is induced by Fc γ R signaling in human monocytes and dendritic cells. Journal of Immunology 2007 178 7 4033 4038 2-s2.0-33947637808 (Pubitemid 46492351)
129. Jin T., Guo F., Kim S., Howard A., Zhang Y., X-ray crystal structure of TNF ligand family member TL1A at 2.1 Å Biochemical and Biophysical Research Communications 2007 364 1 1 6 2-s2.0-35348946401 10.1016/j.bbrc.2007. 09.097 (Pubitemid 47599439)
130. Shih D. Q., Kwan L. Y., Chavez V., Cohavy O., Gonsky R., Chang E. Y., Chang C., Elson C. O., Targan S. R., Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. European Journal of Immunology 2009 39 11 3239 3250 2-s2.0-70449417564 10.1002/eji.200839087
131. Chinnaiyan A. M., O'Rourke K., Yu G., Lyons R. H., Garg M., Duan D. R., Xing L., Gentz R., Ni J., Dixit V. M., Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996 274 5289 990 992 2-s2.0-10544236916 10.1126/science.274.5289.990 (Pubitemid 26398422)
132. Kang Y. J., Kim W. J., Bae H. U., Kim D., Park Y. B., Park J., Kwon B. S., Lee W., Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine 2005 29 5 229 235 2-s2.0-14744279915 10.1016/j.cyto.2004.12.001 (Pubitemid 40326609)
133. Papadakis K. A., Prehn J. L., Landers C., Han Q., Luo X., Cha S. C., Wei P., Targan S. R., TL1A synergizes with IL-12 and IL-18 to enhance IFN- γ production in human T cells and NK cells. Journal of Immunology 2004 172 11 7002 7007 2-s2.0-2442689136 (Pubitemid 38669141)
134. Cavallini C., Lovato O., Bertolaso A., Pacelli L., Zoratti E., Zanolin E., Krampera M., Zamò A., Tecchio C., Cassatella M. A., Pizzolo G., Scupoli M. T., The TNF-Family Cytokine TL1A Inhibits Proliferation of Human Activated B Cells. PLoS ONE 2013 8 4 2-s2.0-84875637013 10.1371/journal.pone. 0060136 e60136
135. Papadakis K. A., Zhu D., Prehn J. L., Landers C., Avanesyan A., Lafkas G., Targan S. R., Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN- γ production by peripheral blood and mucosal CCR9+ T lymphocytes. Journal of Immunology 2005 174 8 4985 4990 2-s2.0-17044413324
136. Yang C. R., Hsieh S. L., Teng C. M., Ho F., Su W., Lin W., Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Research 2004 64 3 1122 1129 2-s2.0-0842347481 10.1158/0008-5472.CAN-03-0609 (Pubitemid 38176919)
137. Wen L., Zhuang L., Luo X., Wei P., TL1A-induced NF- B activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. Journal of Biological Chemistry 2003 278 40 39251 39258 2-s2.0-0141531101 10.1074/jbc.M305833200 (Pubitemid 37221829)
138. Slebioda T. J., Rowley T. F., Ferdinand J. R., Willoughby J. E., Buchan S. L., Taraban V. Y., Al-Shamkhani A., Triggering of TNFRSF25 promotes CD8+ T-cell responses and anti-tumor immunity. European Journal of Immunology 2011 41 9 2606 2611 2-s2.0-80052145580 10.1002/eji.201141477
139. Takedatsu H., Michelsen K. S., Wei B., Landers C. J., Thomas L. S., Dhall D., Braun J., Targan S. R., TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 2008 135 2 552 567 2-s2.0-48549106477 10.1053/j.gastro.2008.04. 037
140. Kamada N., Hisamatsu T., Honda H., Kobayashi T., Chinen H., Takayama T., Kitazume M. T., Okamoto S., Koganei K., Sugita A., Kanai T., Hibi T., TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflammatory Bowel Diseases 2010 16 4 568 575 2-s2.0-77949514515 10.1002/ibd.21124
141. Wu S. F., Liu T. M., Lin Y. C., Sytwu H., Juan H., Chen S., Shen K., Hsi S., Hsieh S., Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. Journal of Leukocyte Biology 2004 75 2 293 306 2-s2.0-0842266763 10.1189/jlb.0303119 (Pubitemid 38174587)
142. Hsu T. L., Chang Y. C., Chen S. J., Liu Y., Chiu A. W., Chio C., Chen L., Hsieh S., Modulation of dendritic cell differentiation and maturation by decoy receptor 3. Journal of Immunology 2002 168 10 4846 4853 2-s2.0-0037093990 (Pubitemid 34495945)
143. Meylan F., Song Y.-J., Fuss I., Villarreal S., Kahle E., Malm I.-J., Acharya K., Ramos H. L., Lo L., Mentink-Kane M. M., Wynn T. A., Migone T.-S., Strober W., Siegel R. M., The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunology 2011 4 2 172 185 2-s2.0-79551529001 10.1038/mi.2010.67
144. Taraban V. Y., Slebioda T. J., Willoughby J. E., Buchan S. L., James S., Sheth B., Smyth N. R., Thomas G. J., Wang E. C. Y., Al-Shamkhani A., Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunology 2011 4 2 186 196 2-s2.0-79551556334 10.1038/mi.2010.70
145. Khan S. Q., Tsai M. S., Schreiber T. H., Wolf D., Deyev V. V., Podack E. R., Cloning, expression, and functional characterization of TL1A-Ig. Journal of Immunology 2013 190 4 1540 1550 2-s2.0-84873546540 10.4049/jimmunol.1201908
146. Kakuta Y., Ueki N., Kinouchi Y., Negoro K., Endo K., Nomura E., Takagi S., Takahashi S., Shimosegawa T., TNFSF15 transcripts from risk haplotype for Crohn's disease are overexpressed in stimulated T cells. Human Molecular Genetics 2009 18 6 1089 1098 2-s2.0-61849167054 10.1093/hmg/ddp005
147. Michelsen K. S., Thomas L. S., Taylor K. D., Yu Q. T., Mei L., Landers C. J., Derkowski C., McGovern D. P. B., Rotter J. I., Targan S. R., IBD-associated TL1A gene (TNFSFI5) haplotypes determine increased expression of TL1A protein. PLoS ONE 2009 4 3 2-s2.0-61849115157 10.1371/journal.pone.0004719 e4719
148. Jin S., Chin J., Seeber S., Niewoehner J., Weiser B., Beaucamp N., Woods J., Murphy C., Fanning A., Shanahan F., Nally K., Kajekar R., Salas A., Planell N., Lozano J., Panes J., Parmar H., Demartino J., Narula S., Thomas-Karyat D. A., TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNF α from CD3+CD161+ T cells to exacerbate gut inflammation. Mucosal Immunology 2013 6 5 886 899 2-s2.0-84883182349 10.1038/mi.2012.124
149. Cohavy O., Shih D. Q., Doherty T. M., Cd161 defines effector T cells that express light and respond to Tl1a-Dr3 signaling. European Journal of Microbiology and Immunology 2011 1 1 70 79 10.1556/EuJMI.1.2011.1.9
150. Kleinschek M. A., Boniface K., Sadekova S., Grein J., Murphy E. E., Turner S. P., Raskin L., Desai B., Faubion W. A., De Malefyt R. W., Pierce R. H., McClanahan T., Kastelein R. A., Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. Journal of Experimental Medicine 2009 206 3 525 534 2-s2.0-63449133361 10.1084/jem.20081712
151. Strober W., Fuss I. J., Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011 140 6 1756 1767 2-s2.0-79955563439 10.1053/j.gastro.2011.02.016
152. Tauzin S., Debure L., Moreau J., Legembre P., CD95-mediated cell signaling in cancer: mutations and post-translational modulations. Cellular and Molecular Life Sciences 2012 69 8 1261 1277 2-s2.0-84860863775 10.1007/s00018-011-0866-4
153. Lettau M., Paulsen M., Schmidt H., Janssen O., Insights into the molecular regulation of FasL (CD178) biology. European Journal of Cell Biology 2011 90 6-7 456 466 2-s2.0-79955467862 10.1016/j.ejcb.2010.10.006
154. O'Reilly L. A., Tai L., Lee L., Kruse E. A., Grabow S., Fairlie W. D., Haynes N. M., Tarlinton D. M., Zhang J., Belz G. T., Smyth M. J., Bouillet P., Robb L., Strasser A., Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009 461 7264 659 663 2-s2.0-70349694386 10.1038/nature08402
155. Moller P., Koretz K., Leithauser F., Bruderlein S., Henne C., Quentmeier A., Krammer P. H., Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. International Journal of Cancer 1994 57 3 371 377 2-s2.0-0028246885 10.1002/ijc.2910570314 (Pubitemid 24168612)
156. Möller P., Walczak H., Riedl S., Sträter J., Krammer P. H., Paneth cells express high levels of CD95 ligand transcripts: a unique property among gastrointestinal epithelia. American Journal of Pathology 1996 149 1 9 13 2-s2.0-0029982827 (Pubitemid 26230972)
157. Pinkoski M. J., Brunner T., Green D. R., Lin T., Fas and Fas ligand in gut and liver. American Journal of Physiology-Gastrointestinal and Liver Physiology 2000 278 3 G354 G366 2-s2.0-0034062699 (Pubitemid 30152480)
158. Strater J., Wellisch I., Riedl S., Walczak H., Koretz K., Tandara A., Krammer P. H., Moller P., CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 1997 113 1 160 167 2-s2.0-0030981633 10.1016/S0016-5085(97)70091-X (Pubitemid 27281770)
159. Strater J., Moller P., Expression and function of death receptors and their natural ligands in the intestine. Annals of the New York Academy of Sciences 2000 915 162 170 (Pubitemid 32059377)
160. Seidelin J. B., Nielsen O. H., Attenuated apoptosis response to Fas-ligand in active ulcerative colitis. Inflammatory Bowel Diseases 2008 14 12 1623 1629 2-s2.0-59849117799 10.1002/ibd.20629
161. Park S. M., Chen L., Zhang M., Ashton-Rickardt P., Turner J. R., Peter M. E., CD95 is cytoprotective for intestinal epithelial cells in colitis. Inflammatory Bowel Diseases 2010 16 6 1063 1070 2-s2.0-77952722978 10.1002/ibd.21195
162. Merger M., Viney J. L., Borojevic R., Steele-Norwood D., Zhou P., Clark D. A., Riddell R., Maric D., Podack E. R., Croitoru K., Defining the roles of perforin, Fas/FasL, and tumour necrosis factor α in T cell induced mucosal damage in the mouse intestine. Gut 2002 51 2 155 163 2-s2.0-0036073328 10.1136/gut.51.2.155 (Pubitemid 34791439)
163. Monteleone I., Monteleone G., Fina D., Caruso R., Petruzziello C., Calabrese E., Biancone L., Pallone F., A functional role of flip in conferring resistance of Crohn's disease lamina propria lymphocytes to FAS-mediated apoptosis. Gastroenterology 2006 130 2 389 397 2-s2.0-32044433980 10.1053/j.gastro.2005.10.021 (Pubitemid 43202038)
164. Ina K., Itoh J., Fukushima K., Kusugami K., Yamaguchi T., Kyokane K., Imada A., Binion D. G., Musso A., West G. A., Dobrea G. M., McCormick T. S., Lapetina E. G., Levine A. D., Ottaway C. A., Fiocchi C., Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. Journal of Immunology 1999 163 2 1081 1090 2-s2.0-0033565302 (Pubitemid 29328123)
165. Boirivant M., Marini M., Di Felice G., Pronio A. M., Montesani C., Tersigni R., Strober W., Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 1999 116 3 557 565 2-s2.0-0033011679 (Pubitemid 29106763)
166. Suzuki A., Sugimura K., Ohtsuka K., Hasegawa K., Suzuki K., Ishizuka K., Mochizuki T., Honma T., Narisawa R., Asakura H., Fas/Fas ligand expression and characteristics of primed CD45RO+ T cells in the inflamed mucosa of ulcerative colitis. Scandinavian Journal of Gastroenterology 2000 35 12 1278 1283 2-s2.0-17744396891 10.1080/003655200453629 (Pubitemid 32051642)
167. Hehlgans T., Pfeffer K., The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005 115 1 1 20 2-s2.0-17944371991 10.1111/j.1365-2567.2005. 02143.x (Pubitemid 40598088)
168. Paulsen M., Valentin S., Mathew B., Adam-Klages S., Bertsch U., Lavrik I., Krammer P. H., Kabelitz D., Janssen O., Modulation of CD4+ T-cell activation by CD95 co-stimulation. Cell Death and Differentiation 2011 18 4 619 631 2-s2.0-79952629569 10.1038/cdd.2010.134
169. Suzuki I., Fink P. J., Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. Journal of Experimental Medicine 1998 187 1 123 128 2-s2.0-0031973637 10.1084/jem.187.1.123 (Pubitemid 28044827)
170. Suzuki I., Fink P. J., The dual functions of Fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America 2000 97 4 1707 1712 2-s2.0-0034652356 10.1073/pnas.97.4.1707 (Pubitemid 30118507)
171. Suzuki I., Martin S., Boursalian T. E., Beers C., Fink P. J., Fas ligand costimulates the in vivo proliferation of CD8+ T cells. Journal of Immunology 2000 165 10 5537 5543 2-s2.0-0034669982
172. Shi G., Luo H., Wan X., Salcedo T. W., Zhang J., Wu J., Mouse T cells receive costimulatory signals from LIGHT, a TNF family member. Blood 2002 100 9 3279 3286 2-s2.0-0036838630 10.1182/blood-2002-05-1404 (Pubitemid 35217078)
173. Mauri D. N., Ebner R., Montgomery R. I., Kochel K. D., Cheung T. C., Yu G., Ruben S., Murphy M., Eisenberg R. J., Cohen G. H., Spear P. G., Ware C. F., LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 1998 8 1 21 30 2-s2.0-0031907988 10.1016/S1074-7613(00)80455-0 (Pubitemid 28097820)
174. Zhai Y., Guo R., Hsu T., Yu G., Ni J., Kwon B. S., Jiang G., Lu J., Tan J., Ugustus M., Carter K., Rojas L., Zhu F., Lincoln C., Endress G., Xing L., Wang S., Oh K., Gentz R., Ruben S., Lippman M. E., Hsieh S., Yang D., LIGHT, a novel ligand for lymphotoxin β receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. Journal of Clinical Investigation 1998 102 6 1142 1151 2-s2.0-0032530318 (Pubitemid 28436274)
175. Shaikh R. B., Santee S., Granger S. W., Butrovich K., Cheung T., Kronenberg M., Cheroutre H., Ware C. F., Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. Journal of Immunology 2001 167 11 6330 6337 2-s2.0-0035576394 (Pubitemid 33081564)
176. Jungbeck M., Daller B., Federhofer J., Wege A. K., Wimmer N., Männel D. N., Hehlgans T., Neutralization of LIGHT ameliorates acute dextran sodium sulphate-induced intestinal inflammation. Immunology 2009 128 3 451 458 2-s2.0-70349669242 10.1111/j.1365-2567.2009.03131.x
177. Bamias G., Kaltsa G., Siakavellas S. I., Gizis M., Margantinis G., Zampeli E., Vafiadis-Zoumboulis I., Michopoulos S., Daikos G. L., Ladas S. D., Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease. Digestive and Liver Disease 2012 44 1 30 36 2-s2.0-83855162827 10.1016/j.dld.2011.09.002
178. Bamias G., Kaltsa G., Siakavellas S. I., Papaxoinis K., Zampeli E., Michopoulos S., Zouboulis-Vafiadis I., Ladas S. D., High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clinical Immunology 2010 137 2 242 249 2-s2.0-77957302227 10.1016/j.clim.2010.07.001
179. Funke B., Autschbach F., Kim S., Lasitschka F., Strauch U., Rogler G., Gdynia G., Li L., Gretz N., Macher-Goeppinger S., Sido B., Schirmacher P., Meuer S. C., Roth W., Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009 58 4 483 491 2-s2.0-63849290926 10.1136/gut.2008.148908
180. Brost S., Koschny R., Sykora J., Stremmel W., Lasitschka F., Walczak H., Ganten T. M., Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. Pathology Research and Practice 2010 206 1 43 50 2-s2.0-73649099092 10.1016/j.prp.2009.09.005
181. Wiley S. R., Winkles J. A., TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine and Growth Factor Reviews 2003 14 3-4 241 249 2-s2.0-0038320242 10.1016/S1359- 6101(03)00019-4 (Pubitemid 36693144)
182. Michaelson J. S., Wisniacki N., Burkly L. C., Putterman C., Role of TWEAK in lupus nephritis: a bench-to-bedside review. Journal of Autoimmunity 2012 39 3 130 142 2-s2.0-84865391444 10.1016/j.jaut.2012.05.003
183. Schneider P., Schwenzer R., Haas E., TWEAK can induce cell death via endogenous TNF and TNF receptor 1. European Journal of Immunology 1999 29 6 1785 1792 (Pubitemid 29265533)
184. Wicovsky A., Salzmann S., Roos C., Ehrenschwender M., Rosenthal T., Siegmund D., Henkler F., Gohlke F., Kneitz C., Wajant H., TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death and Differentiation 2009 16 11 1445 1459 2-s2.0-70350007940 10.1038/cdd.2009.80